Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.
What's in the News
- NeoGenomics will present new research at the International Society of Liquid Biopsy Annual Congress 2025, demonstrating high concordance between its updated RaDaR ST and RaDaR 1.0 assays for molecular residual disease detection in solid tumors and highlighting multiple studies on liquid biopsy and genomic profiling. (Key Developments)
- The company reaffirmed its 2025 earnings guidance, projecting consolidated revenue between $720 million and $726 million, with a net loss expected between $116 million and $108 million. (Key Developments)
- NeoGenomics announced new MRD assay data presentations at the European Society for Medical Oncology Congress 2025, highlighting its RaDaR ST assay for use in oncology drug development and showcasing its capabilities in personalized MRD panel design for real-time tumor monitoring. (Key Developments)
- A U.S. District Court invalidated certain patents Natera had asserted against NeoGenomics’ RaDaR test, with Natera evaluating its legal options. Other patent claims, including those underpinning previous injunctions, remain unaffected. (Key Developments)
Valuation Changes
- The Fair Value Estimate has increased from $11.72 to $13.06, reflecting a moderate upward adjustment.
- The Discount Rate has risen slightly, from 6.78% to 6.96%.
- The Revenue Growth projection is up modestly, from 9.67% to 9.88%.
- The Net Profit Margin forecast has increased fractionally, from 5.46% to 5.48%.
- The Future P/E Ratio estimate has gone up from 36.9x to 40.87x, indicating higher expected valuation multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.